Creso Pharma launches First Product and signs China Distribution Agreement

Creso Pharma have had a hugely successful couple of weeks with two exciting pieces of news in the past week which have helped lift the stock to record highs.

  • First Product Launch for Creso Pharma
  • China Commercial Distribution Agreement signing

The launch of its debut product was in the animal health sector. The first product is called Anibidiol which is produced in partnership with Virbac who are the world's 7th largest Animal Pharma Company with €872 million turnover in FY16. Creso also included in this announcement an update for the market regarding its first human prodcut, CannaQix which is is on trakc for a Q1 2018 launch. 

The signing of the China Distribution agreement with Kingdom Group, a company with AUD $90.6m Revenue in H1FY17 and assets over AUD $279m can be viewed as a hugely significant step for Creso Pharma. The agreement gives Creso a strategic foothold in China with Kingdom assisting with importing, marketing and distribution of Creso into China. Kingdom and Creso habe also agreed to Co-develop innovative prodcuts specifically for the Chinese market. 

Creso Pharma Shares closed at all time highs of $1.245 on November 21 following these strong announcements. 

quote

"We are very excited about the launch of anibidiol in Switzerland and thrilled to be working in partnership with Virbac, such a well-established global company in the animal health field."

"When coupled with the very exciting partnership with Kingdom that gives Creso a strategic foothold in China and Asia. These are very ezxciting developments for us as a company and are important steps in our plans for growth in key markets and sectors."

CRESO PHARMA CEO, DR. MIRI HALPERIN WERNLI

What we do at EverBlu Capital Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vestibulum erat leo, lobortis ut dapibus id, tincidunt ac erat. Phasellus placerat fermentum elit at cursus. Nunc pellentesque lectus sed nibh tempor.

EverBlu Corporate

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vestibulum erat leo, lobortis ut dapibus id, tincidunt ac erat. Phasellus placerat fermentum elit at cursus. Nunc pellentesque lectus sed nibh tempor, eu auctor arcu dignissim. In euismod luctus ligula id dignissim vivamus lorem ipsum dolor sit amet…

Learn more

EverBlu Wealth

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vestibulum erat leo, lobortis ut dapibus id, tincidunt ac erat. Phasellus placerat fermentum elit at cursus. Nunc pellentesque lectus sed nibh tempor, eu auctor arcu dignissim. In euismod luctus ligula id dignissim vivamus lorem ipsum dolor sit amet…

Learn more

EverBlu Research

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vestibulum erat leo, lobortis ut dapibus id, tincidunt ac erat. Phasellus placerat fermentum elit at cursus. Nunc pellentesque lectus sed nibh tempor, eu auctor arcu dignissim. In euismod luctus ligula id dignissim vivamus lorem ipsum dolor sit amet…

Learn more

What they say about us